Daklinza Disease Interactions
There is 1 disease interaction with Daklinza (daclatasvir).
Daclatasvir (applies to Daklinza) cirrhosis
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis
In clinical studies, HCV genotype 3-infected patients with cirrhosis receiving daclatasvir in combination with sofosbuvir for 12 weeks demonstrated reduced sustained virologic response (SVR12) rates. In addition, in hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfected patients, the use of daclatasvir may cause a reactivation of the HBV. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. It is recommended to test all patients for evidence of prior HBV infection before initiating therapy with daclatasvir. Close monitoring for signs and symptoms of hepatitis flare or HBV reactivation is recommended during HCV treatment with daclatasvir and during after treatment follow-up. Consider appropriate management for patients with HBV infection as clinically indicated.
References (1)
- (2015) "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb
Switch to consumer interaction data
Daklinza drug interactions
There are 270 drug interactions with Daklinza (daclatasvir).
Report options
More about Daklinza (daclatasvir)
- Daklinza consumer information
- Check interactions
- Compare alternatives
- Reviews (10)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: NS5A inhibitors
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
